echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Renren Biotech's IPO will promote the development of 6 innovative products.

    Renren Biotech's IPO will promote the development of 6 innovative products.

    • Last Update: 2020-09-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On August 13th, Shanghai Ren association biopharmaceutical Co., Ltd. (referred to as Ren association bio) in Shanghai Stock Exchange, the IPO application has passed the Shanghai Municipal Committee meeting, the sponsor is Guotai Junan.
    , according to the prospectos, the IPO is expected to raise 3,005 million yuan, of which about 1.24 billion yuan will be used for new drug research and development projects.
    , the company's first innovative biopharmaceous benaglutide injection (Yishengtai) has been commercialized, mainly for the treatment of type 2 diabetes.
    founded in 1999, focusing on the research and development, production and sales of innovative drugs in the field of major diseases, the chairman of the board of directors is Mr. Sang Willing.
    the company's official website announcement, in 2014, it completed the reform of the shareholding system, the same year in China's small and medium-sized enterprises share transfer system listed.
    focuses on innovative drugs in the field of diabetes and has a wealth of research and development pipelines in the field of metabolism, cardiovascular and oncology.
    benaglupe injection: approved in China in 2016, adaptively for controlling blood sugar in adults with type 2 diabetes and for patients with poor blood sugar control with metformin alone.
    , according to the prospecto, the product is an all-human GLP-1 class of drugs, in terms of effectiveness, safety has a unique advantage.
    GLP-1 is a class of bowel-promoting insulin hormones whose main physiological effect is to reduce post-meal blood sugar dependently on blood sugar concentration.
    , it can also act on the central nervous system when eating to produce a feeling of satiety, reducing the urge to eat.
    Benaglutide injections are injections made from E. coli, which efficiently expresses the genes of Benaglutide (human glucosin polypeptide-1 (7-36)), fermented, isolated and highly purified.
    BEM-014: New adaptations for Benaglutide injections in the field of overweight/obesity treatment.
    According to the prospectuse, BEM-041 and GLP-1 bind, mainly by regulating the appetite center, enhance satiety, delay stomach emptying and other mechanisms to improve the patient's eating habits, reduce energy intake, so as to achieve weight loss, improve blood lipids and other purposes.
    , the product has been approved by china's National Drug Administration (NMPA) to enter phase 3 clinical research phase, and clinical research in the United States.
    addition, Ren Society Bio plans to conduct clinical trials on weight loss among Chinese adolescents and non-clinical and clinical studies on pumping weight loss (China and the United States) on this product.
    BEM-050: Benaglutide is a new adaptation in the treatment of non-alcoholic fatty liver disease/hepatitis (NAFLD/NASH).
    According to the prospectus, BEM-050 can be used in NAFLD/NASH by reducing weight, improving lipid disorders, improving insulin sensitivity, reducing body transaminase levels and inflammatory factor levels, and improving liver fibrosis.
    , the product is conducting preclinical studies and is about to declare IND. in addition to the
    Renren Society Biodevested Pipeline (Photo Source: Resources) in addition, Renren Bio has a number of products in the preclinical research phase, such as: BEM-012: new GLP-1 subject agonists.
    the product has the hope of achieving more convenient and effective control of fasting blood sugar, maintaining weight loss and further improving patient compliance.
    BEM-041: Benaglutide and basic insulin compound preparation.
    GLP-1 in physiological conditions promotes and synergies with insulin, and the product is expected to provide patients with more treatment options for reducing basic and post-meal blood sugar, controlling blood sugar fluctuations, lower risk, and long-term combined benefits.
    BEM-015: Anticoagulant factor monoclonal antibody, in the anticoagulant, improve the thrombosis after thrombosis at the same time reduce the tendency of bleeding, widely used in the prevention of re-events after the heart attack / cerebral infarction.
    BEM-032: anti-vascular growth and immunosuppressive antibodies to better target the treatment of leukemia.
    BEM-033: Monoclonal antibodies of a new generation of immuno-checkpoint inhibitors, widely applicable to solid tumors in the future, renal biology will continue to carry out endocrine as the core, taking into account the cardiovascular and tumor treatment field of bio-innovative drug independent research and development.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.